The U.S. Food and Drug Administration has approved a Teva Pharmaceutical Industries drug, Austedo, for the treatment of chorea stemming from Huntington's disease.
According to Teva, the FDA approval was based on results from a late-stage study of Austedo in reducing chorea in patients with the degenerative disorder. The company also claims the approval was held up by regulators' desire for more blood studies.
The news, which according to Reuters analysts are forecasting annual sales up to $850 million by 2023, comes after a rocky time for Teva following its CEO stepping down.
Read the Reuters report